Drug Profile
BNT 211
Alternative Names: Anti-claudin 6 CAR T-cell therapy - BioNTech; Anti-claudin 6 chimeric antigen receptor cell therapy - BioNTech; Anti-CLDN6 chimeric antigen receptor cell therapy - BioNTech; BNT-211; CLDN6 CAR-T therapy - BioNTechLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator BioNTech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 09 Jan 2024 BioNTech plans a pivotal phase II trial in Germ cell cancer (Second-line therapy or greater) (IV, Infusion), in 2024
- 23 Oct 2023 Updated adverse events and efficacy data from a phase I/II trial in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 07 Aug 2023 Efficacy data from a phase I/II trial in Solid tumors released by BioNTech